Id: acc0131
Group: 1sens
Protein: FOXO3A
Gene Symbol: FOXO3
Protein Id: O43524
Protein Name: FOXO3_HUMAN
PTM: phosphorylation
Site: Tyr
Site Sequence:
Disease Category: Cancer
Disease: Breast Cancer
Disease Subtype: HER2+
Disease Cellline: SK-BR-3
Disease Info:
Drug: lapatinib
Drug Info: "Lapatinib is a targeted therapy drug used in combination with capecitabine for the treatment of HER2-overexpressing advanced or metastatic breast cancer in patients who have received prior anthracycline, taxane, and trastuzumab-based therapies."
Effect: modulate
Effect Info: "In the responsive breast cancer cell lines exposed to lapatinib, phosphorylated Akt and Akt-mediated FOXO3A phosphorylation also decreased."
Note: site unclear
Score: 4.0
Pubmed(PMID): 17513611
Sentence Index:
Sentence:

Sequence & Structure:

MAEAPASPAPLSPLEVELDPEFEPQSRPRSCTWPLQRPELQASPAKPSGETAADSMIPEEEDDEDDEDGGGRAGSAMAIGGGGGSGTLGSGLLLEDSARVLAPGGQDPGSGPATAAGGLSGGTQALLQPQQPLPPPQPGAAGGSGQPRKCSSRRNAWGNLSYADLITRAIESSPDKRLTLSQIYEWMVRCVPYFKDKGDSNSSAGWKNSIRHNLSLHSRFMRVQNEGTGKSSWWIINPDGGKSGKAPRRRAVSMDNSNKYTKSRGRAAKKKAALQTAPESADDSPSQLSKWPGSPTSRSSDELDAWTDFRSRTNSNASTVSGRLSPIMASTELDEVQDDDAPLSPMLYSSSASLSPSVSKPCTVELPRLTDMAGTMNLNDGLTENLMDDLLDNITLPPSQPSPTGGLMQRSSSFPYTTKGSGLGSPTSSFNSTVFGPSSLNSLRQSPMQTIQENKPATFSSMSHYGNQTLQDLLTSDSLSHSDVMMTQSDPLMSQASTAVSAQNSRRNVMLRNDPMMSFAAQPNQGSLVNQNLLHHQHQTQGALGGSRALSNSVSNMGLSESSSLGSAKHQQQSPVSQSMQTLSDSLSGSSLYSTSANLPVMGHEKFPSDLDLDMFNGSLECDMESIIRSELMDADGLDFNFDSLISTQNVVGLNVGNFTGAKQASSQSWVPG

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

FOXO3-Ser12
Cancer Intensity
BRCA 1.448
COAD
HGSC
ccRCC -0.214
GBM -0.835
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC -0.399
FOXO3-Ser215
Cancer Intensity
BRCA 0.997
COAD
HGSC
ccRCC -0.25
GBM 0.536
HNSC 0.096
LUAD -1.221
LUSC 1.549
non_ccRCC -0.465
PDAC
UCEC -1.241
FOXO3-Ser253
Cancer Intensity
BRCA -0.252
COAD 0.934
HGSC -0.476
ccRCC -0.796
GBM -1.043
HNSC 0.586
LUAD 1.25
LUSC 1.2
non_ccRCC -1.739
PDAC 0.756
UCEC -0.42
FOXO3-Ser280
Cancer Intensity
BRCA 1.013
COAD
HGSC -2.32
ccRCC 0.29
GBM
HNSC 0.403
LUAD 0.416
LUSC 0.374
non_ccRCC -0.177
PDAC
UCEC 0.001
FOXO3-Ser284
Cancer Intensity
BRCA 0.044
COAD 0.271
HGSC -2.973
ccRCC 0.334
GBM 0.115
HNSC 0.638
LUAD 0.247
LUSC 0.308
non_ccRCC 0.38
PDAC 0.476
UCEC 0.161
FOXO3-Ser294
Cancer Intensity
BRCA 0.707
COAD
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC -0.707
UCEC
FOXO3-Ser297
Cancer Intensity
BRCA
COAD 0.707
HGSC -0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
FOXO3-Ser299
Cancer Intensity
BRCA
COAD 0.762
HGSC -1.132
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC 0.37
UCEC
FOXO3-Ser311
Cancer Intensity
BRCA -2.162
COAD 1.528
HGSC 0.452
ccRCC -0.252
GBM 0.305
HNSC 0.329
LUAD
LUSC 0.179
non_ccRCC
PDAC 0.267
UCEC -0.646
FOXO3-Ser315
Cancer Intensity
BRCA
COAD
HGSC -1.741
ccRCC 0.739
GBM
HNSC
LUAD 0.142
LUSC 0.559
non_ccRCC
PDAC
UCEC 0.3
FOXO3-Ser411
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM -0.707
HNSC 0.707
LUAD
LUSC
non_ccRCC
PDAC
UCEC
FOXO3-Ser412
Cancer Intensity
BRCA
COAD
HGSC
ccRCC 0.067
GBM -0.844
HNSC 1.384
LUAD
LUSC
non_ccRCC
PDAC
UCEC -0.606
FOXO3-Ser413
Cancer Intensity
BRCA -0.09
COAD 0.361
HGSC -2.65
ccRCC 0.712
GBM -0.117
HNSC -0.258
LUAD 0.507
LUSC 0.288
non_ccRCC 1.378
PDAC -0.12
UCEC -0.011
FOXO3-Ser425
Cancer Intensity
BRCA
COAD 0.413
HGSC -1.14
ccRCC
GBM
HNSC 0.727
LUAD
LUSC
non_ccRCC
PDAC
UCEC
FOXO3-Ser428
Cancer Intensity
BRCA
COAD 0.707
HGSC -0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
FOXO3-Ser438
Cancer Intensity
BRCA
COAD
HGSC -0.707
ccRCC
GBM
HNSC
LUAD 0.707
LUSC
non_ccRCC
PDAC
UCEC
FOXO3-Ser7
Cancer Intensity
BRCA 2.331
COAD
HGSC
ccRCC -0.162
GBM -1.093
HNSC
LUAD -0.048
LUSC -0.128
non_ccRCC -0.346
PDAC -0.115
UCEC -0.44
FOXO3-Ser75
Cancer Intensity
BRCA 1.265
COAD
HGSC
ccRCC -1.85
GBM
HNSC
LUAD 0.569
LUSC 0.23
non_ccRCC -0.693
PDAC 0.284
UCEC 0.195
FOXO3-Ser85
Cancer Intensity
BRCA 1.102
COAD
HGSC
ccRCC
GBM
HNSC
LUAD -0.85
LUSC
non_ccRCC
PDAC
UCEC -0.252
FOXO3-Thr296
Cancer Intensity
BRCA
COAD 0.707
HGSC -0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
FOXO3-Thr307
Cancer Intensity
BRCA
COAD
HGSC
ccRCC -0.707
GBM
HNSC 0.707
LUAD
LUSC
non_ccRCC
PDAC
UCEC
FOXO3-Thr427
Cancer Intensity
BRCA
COAD -0.707
HGSC 0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
FOXO3-Thr87
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC
LUAD 0.707
LUSC
non_ccRCC
PDAC
UCEC -0.707

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
- - U Nasopharyngeal carcinoma Acetylation 31727006
- - U Renal cell carcinoma Phosphorylation 36923928
- - U X-linked myotubular myopathy Phosphorylation 23695157
- - U Paget's disease Phosphorylation 23262029
- - U Acute myeloid leukemia/acute myelogenous leukemia Phosphorylation 20215543
- - U Asthma Ubiquitination 33837090

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: